06 Jan MS and the Pandemic
Have you ever asked yourself what kind of risk you are in?
Especially if you are taking disease modifying therapies? (DMTs)
There was a case study done where MS patients taking (DMTs), by far the most cases were described when taking anti-CD20 treatment (n=317). The mortality rate of all MS patients was 4% and a further 3% required invasive or non-invasive ventilation.
When looking at the severe and fatal cases, it is particularly noticeable that patients without DMTs, with previous cardiovascular diseases, or with a severe degree disability are at risk. Immunosuppressive therapy itself did not appear to be a substantial risk factor.
Studies show that the COVID-19 pandemic is having an impact on psychological health of patients with relapsing-remitting MS (RRMS)
The researchers found that the main concerns among patients were that someone they know could be infected with COVID-19 or could die from the infection, as well as the lack of specific treatment options.
Regarding RRMS status, the main concerns were that their disease would be worse if they contract COVID-19, that they might experience some difficulties in drug availability, and that they could not go to the hospital as usual.
Today, close to 1 million adults in the united states have been diagnosed with MS. During the COVID-19 pandemic patients have found themselves doing Virtual Reality for doctors appointments. Virtual reality and augmented reality (VR/AR), which were once thought of as simple gamification, have been adopted be medical professionals around the world.
Patients can remotely engage with clinicians, where they can be guided with a treatment plan that is personalized.